CTMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CytomX Therapeutics Inc (CTMX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as significant analyst upgrades and hedge fund buying, the company's poor financial performance, insider selling, and lack of recent trading signals suggest that waiting for further clarity on the company's financial recovery or additional positive developments would be prudent.
The technical indicators are mixed. The MACD histogram is negative and contracting, RSI is neutral at 43.53, and moving averages are converging. The stock is trading near a support level of 4.114, but there is no clear bullish signal.
Analysts have significantly raised price targets, with the highest being $17, citing promising Phase 1 data for Varseta-M and its potential to disrupt the colorectal cancer treatment market.
Hedge funds are heavily buying, with a 1979% increase in the last quarter.
Insiders are selling, with a 457.87% increase in selling activity over the last month.
The company's financial performance in Q4 2025 was extremely poor, with revenue dropping by 98.26% YoY and net income plummeting by 256.35%.
The company's financials for Q4 2025 were weak, with revenue dropping to $663,000 (-98.26% YoY), net income falling to -$29.51M (-256.35% YoY), and EPS declining to -$0.17 (-177.27% YoY). However, gross margin remained stable at 100%.
Analysts are overwhelmingly positive, with multiple firms raising price targets significantly (up to $17) and maintaining Buy or Overweight ratings. The updates on Phase 1 data for Varseta-M have been described as exceeding benchmarks and setting a new precedent for late-line colorectal cancer treatment.
